rovadicitinib

Rovadicitinib is a novel, oral small molecule drug that acts as a dual inhibitor of Janus kinase 1 and 2 (JAK1/2) and Rho-associated protein kinase 1 and 2 (ROCK1/2). This first-in-class agent targets both inflammatory and fibrotic pathways, making it particularly promising for diseases with these components. Rovadicitinib is being developed primarily for the treatment of chronic graft-versus-host disease (cGVHD), especially in patients who are glucocorticoid-refractory or -dependent. It has also been investigated in myelofibrosis and hemophagocytic lymphohistiocytosis. Clinical trials have shown high response rates, good tolerability, and significant steroid-sparing effects in cGVHD patients[1][5][7][8].

Brand names

Rovadicitinib

Other names

rovadicitinib1948242-59-8(3R)-3-[3-amino-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-3-cyclopentylpropanenitrile